Opexa Therapeutics Reports 2nd Qtr 2012 Financial Results and Provides Corporate Update.

Předmět:	FINANCIAL statements INTERLEUKINS MULTIPLE sclerosis BONDS (Finance) STOCK warrants THERAPEUTICS
Zdroj:	Biomedical Market Newsletter; 8/28/2012, Vol. 21, p1-5, 5p
Abstrakt:	The article focuses on the financial report of the health care firm Opexa Therapeutics Inc. for the second quarter of the year 2012. It informs that Opexa is developing T-cell therapy for multiple sclerosis (MS) and it has closed the finance of 4.1 million U.S. dollars by proceeding through a private sector finance consisting financial notes and warrants to purchase shares.
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu